Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05179603
Other study ID # ACT16941
Secondary ID U1111-1251-5834M
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date December 7, 2021
Est. completion date January 14, 2025

Study information

Verified date March 2024
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The is a phase 2 multi-cohort, un-controlled, non-randomized, open-label, multi-center study assessing the antitumor activity and safety of non-alpha interleukin (IL-2) SAR444245 with or without other anticancer therapies in participants aged 12 years and older with relapsed or refractory B cell lymphoma. This study is structured as a master protocol with separate sub studies designed to investigate the use of SAR444245 either with or without other anticancer therapies for the treatment of relapsed or refractory B cell lymphoma. Substudy 1-Cohort A aims to establish safety and preliminary anti-tumor activity for non-alpha interleukin (IL-2) SAR444245 combined with the anti-PD1 antibody, pembrolizumab in trial participants with classic Hodgkin lymphoma (cHL) who are anti-PD-(L)1-naive and have received at least 2 or 3 lines of systemic therapy. Substudy 3-Cohort C1 aims to establish safety and preliminary anti-tumor activity for SAR444245 as monotherapy in trial participants with diffuse large B-cell lymphoma (DLBCL). Trial participants in this study must have received at least 2 lines of systemic therapy and have either stable or progressive disease 1-3 months post Health Authority approved Chimeric Antigen Receptor T-cell (CAR-T) treatment when given as last systemic treatment prior to study enrollment.


Description:

The duration of the study for an individual patient will start from the signature of the main informed consent and include: a screening period of up to 28 days; a treatment period [max] 35 cycles (21 days per cycle) for Cohort A and 52 cycles (14 days per cycle) for Cohort C1 or until occurrence of unacceptable toxicities or until PD; an end-of-treatment visit at least approximately 30 days following the last administration of study drug (or until the patient receives another anticancer therapy, whichever is earlier); and a follow-up visits 3 months after treatment discontinuation and every 3 months thereafter following, until disease progression, or initiation of another antitumor treatment, or death, whichever is earlier.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 14
Est. completion date January 14, 2025
Est. primary completion date September 14, 2023
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - Participants must be = 12 years of age, at the time of signing the informed consent - Disease location amenable to tumor biopsy at baseline - All participants must have a measurable disease - Both male and female participants agree to use approved contraception methods; not pregnant or breastfeeding for female participants; no donation or cryopreservation of eggs (ova, oocytes) for female participants and sperms for male participants. - Capable of giving signed informed consent For cohort A: Histologically or cytologically confirmed diagnosis of classic Hodgkin lymphoma (cHL), must have received at least two prior lines of systemic therapy for cHL, including at least one containing an anthracycline or brentuximab. For cohort C1: Histologically confirmed diagnosis of diffuse large B Cell lymphoma (DLBCL), must have received at least two prior lines of systemic therapy for DLBCL, including one containing a combination of anthracycline and rituximab (or another anti-CD20 agent), with the last line of therapy a Health Authority approved CD19-directed CAR-T therapy. Patients must have BOR (Best Overall Response) of stable disease (SD) or progressive disease (PD) after CD-19 directed CAR-T therapy. Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: - Eastern Cooperative Oncology Group (ECOG) performance status of = 2 (= 16 years old). Lansky Scale (< 16 years old) = 60% - Poor bone marrow reserve - Poor organ function - Participants with baseline oxygen saturation (SpO2) = 92% (without oxygen therapy) - Lymphomatous involvement of the central nervous system - History of allogenic or solid organ transplant - Prior IV or subcutaneous anticancer therapy, investigational agent, major surgery within 21 days prior to initiation of IMP; oral anticancer therapy within 5 half-lives or completed palliative radiotherapy within 21 days prior to initiation of IMP - Has received prior IL-2-based anticancer treatment - Comorbidity requiring corticosteroid therapy - Antibiotic use (excluding topical antibiotics) = 14 days prior to first dose of IMP - Severe or unstable cardiac condition within 6 months prior to starting study treatment - Active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years-Known second malignancy either progressing or requiring active treatment within the last 3 years - Receipt of a live or live attenuated virus vaccination within 28 days of planned treatment start. Seasonal flu vaccines or SARS-CoV-2 vaccine that do not contain live virus are permitted The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.

Study Design


Intervention

Drug:
THOR-707
Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion
Pembrolizumab
Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous infusion

Locations

Country Name City State
Argentina Investigational Site Number : 0320005 Caba Buenos Aires
Chile Investigational Site Number : 1520002 Santiago Reg Metropolitana De Santiago
Chile Investigational Site Number : 1520003 Santiago Reg Metropolitana De Santiago
Chile Investigational Site Number : 1520001 Temuco
Chile Investigational Site Number : 1520004 Vina del Mar Valparaíso
Spain Investigational Site Number : 7240002 Barcelona Barcelona [Barcelona]
Spain Investigational Site Number : 7240001 Hospitalet de Llobregat Barcelona [Barcelona]
Spain Investigational Site Number : 7240004 Madrid / Madrid Madrid, Comunidad De

Sponsors (2)

Lead Sponsor Collaborator
Sanofi Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

Argentina,  Chile,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete Response Rate- Cohort A Cohorts A:
Complete response rate (CRR) defined as the proportion of participants who have a complete response (CR) determined by Investigator per Lugano response criteria 2014.
Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximately 8 months after the last participant receive first dose.
Primary Objective Response Rate- Cohort C1 Cohort C1:
Objective response rate (ORR) defined as the proportion of participants who have CR or partial response (PR) determined by Investigator per Lugano response criteria 2014.
Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximately 8 months after the last participant receive first dose.
Secondary Incidence of Dose-limiting toxicities (DLTs) DLTs assessed during DLT observation period to confirm the dose of SAR444245 when combined with or without other anticancer therapies. 21 days for Cohort A and 28 days for Cohort C1
Secondary Incidence of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and laboratory abnormalities Safety profile of SAR444245 when combined with or without other anticancer therapies assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus gradings. From first investigational medicinal product (IMP) dose up to 30 days for TEAEs or up to 90 days for SAE after the last dose of IMP i.e., up to approximately 27 months
Secondary Objective Response Rate- Cohort A Cohort A:
Objective response rate (ORR) defined as the proportion of participants who have CR or partial response (PR) determined by Investigator per Lugano response criteria 2014.
Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximately 8 months after the last participant receive first dose.
Secondary Time to Response (TTR) TTR defined as the time from the first administration of IMP to the first documented evidence of PR or CR determined by Investigator per Lugano response criteria 2014. From the date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 36 months
Secondary Duration of Response (DoR) DoR defined as the time from first documented evidence of PR or CR until progressive disease (PD) determined by Investigator per Lugano response criteria 2014, or death from any cause, whichever occurs first. From the date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 36 months
Secondary Clinical Benefit Rate (CBR) CBR defined as CR or PR at any time or stable disease (SD) of at least 6 months determined by Investigator per Lugano response criteria 2014. Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximately 8 months after the last participant receive first dose.
Secondary Progression free survival (PFS) PFS defined as the time from the date of first IMP administration to the date of the first documented disease progression determined by Investigator per Lugano response criteria 2014 or death due to any cause, whichever occurs first. From the date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 36 months
Secondary Complete response rate- Cohort C1 Cohort C1:
Complete response rate (CRR) defined as the proportion of participants who have a CR determined by Investigator per Lugano response criteria 2014.
Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximately 8 months after the last participant receive first dose.
Secondary Plasma concentration of SAR444245 Multiple timepoints up to approximately 24 months
Secondary Incidence of anti-drug antibodies (ADAs) against SAR444245 Multiple timepoints up to approximately 24 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05823701 - Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients Phase 2
Completed NCT01691898 - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Recruiting NCT03656835 - Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma N/A
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Active, not recruiting NCT02060656 - Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) Phase 2
Active, not recruiting NCT01653067 - STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma Phase 2
Enrolling by invitation NCT00846157 - Biocell Natural Killer Mixture in Diffuse Large B Cell Lymphoma (DLBCL) Patients Phase 3
Completed NCT00440583 - The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP Phase 2
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Recruiting NCT04981795 - realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Completed NCT01186978 - Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma N/A
Completed NCT01197560 - Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Phase 2/Phase 3
Recruiting NCT03246906 - Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Phase 2
Not yet recruiting NCT05990985 - The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. N/A
Completed NCT02890602 - Erythropoietin for Management of Anemia Caused by Chemotherapy Phase 2
Completed NCT03630159 - Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients Phase 1
Active, not recruiting NCT04529772 - A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) Phase 3
Active, not recruiting NCT02900651 - Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Phase 1
Active, not recruiting NCT02481310 - Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Phase 1/Phase 2